$791 Million is the total value of GREAT POINT PARTNERS LLC's 42 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 40.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BCRX | Sell | BIOCRYST PHARMACEUTICALS | $61,512,000 | +1.0% | 7,622,256 | -4.5% | 7.78% | -18.0% |
| SVRA | Sell | SAVARA INC CMN | $13,771,000 | -45.0% | 1,819,195 | -18.9% | 1.74% | -55.4% |
| ENTA | Sell | ENANTA PHARMACEUTICALS INC | $10,163,000 | -43.5% | 143,481 | -31.8% | 1.28% | -54.1% |
| PTGX | Sell | PROTAGONIST THERAPEUTICS INC | $6,431,000 | -36.4% | 955,618 | -2.7% | 0.81% | -48.4% |
| VYGR | Sell | VOYAGER THERAPEUTICS INC | $3,432,000 | -87.0% | 365,132 | -73.9% | 0.43% | -89.5% |
| MDGL | Sell | MADRIGAL PHARMACEUTICALS INC | $3,100,000 | -64.2% | 27,500 | -31.9% | 0.39% | -70.9% |
| ALNY | Sell | ALNYLAM PHARMACEUTICALS INC | $2,931,000 | -88.8% | 40,197 | -86.6% | 0.37% | -91.0% |
| ARGX | Sell | ARGENX SEsponsored adr | $1,777,000 | -81.8% | 18,500 | -85.7% | 0.22% | -85.2% |
| SNSS | Sell | SUNESIS PHARMACEUTICALS INC | $132,000 | -93.4% | 317,962 | -68.2% | 0.02% | -94.6% |
| CTIC | Exit | CTI BIOPHARMA CORP | $0 | – | -21,441 | -100.0% | -0.01% | – |
| SRRA | Exit | SIERRA ONCOLOGY INC | $0 | – | -490,843 | -100.0% | -0.13% | – |
| ACER | Exit | ACER THERAPEUTICS INC | $0 | – | -58,461 | -100.0% | -0.28% | – |
| ZYME | Exit | ZYMEWORKS INC | $0 | – | -241,970 | -100.0% | -0.59% | – |
| ECYT | Exit | ENDOCYTE INC | $0 | – | -1,606,100 | -100.0% | -4.44% | – |
| EXEL | Exit | EXELIXIS INC | $0 | – | -2,075,000 | -100.0% | -5.73% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTNS, INC CMN | 25 | Q3 2019 | 2.5% |
| IOVANCE BIOTHERAPEUTICS, INC. CMN | 16 | Q1 2021 | 14.3% |
| ZOGENIX INC CMN | 16 | Q4 2019 | 8.8% |
| PTC THERAPEUTICS, INC. CMN | 16 | Q3 2023 | 9.9% |
| EXELIXIS, INC | 16 | Q1 2022 | 7.5% |
| SAGE THERAPEUTICS, INC CMN | 15 | Q3 2021 | 10.8% |
| CYTOKINETICS INC | 15 | Q3 2023 | 5.8% |
| ACADIA PHARMACEUTICALS, INC. | 14 | Q1 2021 | 8.8% |
| ACCELERON PHARMA INC CMN | 14 | Q2 2020 | 8.2% |
| CONNECTURE INC | 13 | Q4 2017 | 25.1% |
View GREAT POINT PARTNERS LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| 89bio, Inc. | February 14, 2023 | 700,000 | 1.4% |
| KalVista Pharmaceuticals, Inc. | February 14, 2023 | 1,055,801 | 3.1% |
| Avalo Therapeutics, Inc. | February 13, 2023 | 974,639 | 7.1% |
| InflaRx N.V.Sold out | February 14, 2022 | 0 | 0.0% |
| ABEONA THERAPEUTICS INC.Sold out | February 16, 2021 | 0 | 0.0% |
| CONSTELLATION PHARMACEUTICALS INC | February 16, 2021 | 1,024,800 | 2.2% |
| GERON CORP | February 16, 2021 | 12,754,228 | 4.0% |
| Millendo Therapeutics, Inc. | February 16, 2021 | 270,000 | 1.4% |
| NextCure, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
| PROTHENA CORP PUBLIC LTD CO | February 16, 2021 | 977,647 | 2.4% |
View GREAT POINT PARTNERS LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View GREAT POINT PARTNERS LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.